Key Takeaways CorMedix beat Q1 estimates as DefenCath revenue climbed on stronger dialysis customer demand.CRMD raised 2026 revenue outlook to $325M-$345M after stronger-than-expected Q1 results.CorMedix posted higher EBITDA and advanced Rezzayo and taurolidine/heparin studies.CorMedix Therapeutics (CRMD) delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents.Net revenue was $127.4 million, up significantly from the year ...